Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 18, 2003, Pages 2973-2976

  Fraley, Mark E ^a   Arrington, Kenneth L ^a   Hambaugh, Scott R ^a   Hoffman, William F ^a   Cunningham, April M ^a   Young, Mary Beth ^a   Hungate, Randall W ^a   Tebben, Andrew J ^a   Rutledge, Ruth Z ^a   Kendall, Richard L ^a   Huckle, William R ^a   McFall, Rosemary C ^a   Coll, Kathleen E ^a   Thomas, Kenneth A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 THIEN 3 YLPYRIDIN 3 YL) 1H INDOLE; ENZYME INHIBITOR; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 12444275599     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00627-9     Document Type: Article

References (30)

1. Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D'Amore P.A., Folkman J. Biochem. Biophys. Res. Commun. 193:1993;631.
2. Giatromanolaki A., Sivridis E., Athanassou N., Zois E., Thorpe P.E., Brekken R.A., Gatter K.C., Harris A.L., Koukourakis I.M., Koukourakis M.I. J. Pathol. 194:2001;101.
3. Detmar M. Dermatol. Sci. 24:2000;S78.
4. For reviews, see: (a) Carmeliet P., Jain R.K. Nature. 407:2000;249 (b) Folkman J. Nat. Med. 1:1995;27.
5. For reviews, see: (a) Carmeliet P., Jain R.K. Nature. 407:2000;249 (b) Folkman J. Nat. Med. 1:1995;27.
6. Zetter B.R. Ann. Rev. Med. 49:1998;407.
7. (a) Hanahan D., Folkman J. Cell. 86:1996;353.
8. (b) Holmgen L., O'Reilly M.S., Folkman J. Nat. Med. 1:1995;149.
9. (a) Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Cancer Res. 60:2000;203.
10. (b) Thomas K.A. J. Biol. Chem. 271:1996;603.
11. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Nature. 362:1993;841.
12. Witte L., Hicklin D., Zhu Z., Pytowski B., Kotanides H., Rockwell P., Bohlen P. Cancer Metastasis Rev. 17:1998;155.
13. (a) Fong T.A.T., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K.P., McMahon G. Cancer Res. 59:1999;99.
14. (b) Drevs J., Hofmann I., Hugenschmidt H., Wittig C., Madjar H., Müller M., Wood J., Martiny-Baron G., Unger C., Marmé D. Cancer Res. 60:2000;4819.
15. (c) Wedge S.R., Ogilvie D.J., Dukes M., Kendrew J., Chester R., Jackson J.A., Boffey S.J., Valentine P.J., Curwen J.O., Musgrove H.L., Graham G.A., Hughes G.D., Thomas A.P., Stokes E.S.E., Curry B., Richmond G.H.P., Wadsworth P.F., Bigley A.L., Hennequin L.F. Cancer Res. 62:2002;4645.
16. For recent reviews, see: (a) Connell R.D. Expert Opin. Ther. Pat. 12:2002;1763 (b) Boyer S.J. Curr. Top. Med. Chem. 2:2002;973 (c) Bilodeau M.T., Fraley M.E., Hartman G.D. Expert Opin. Investig. Drugs. 11:2002;737.
17. For recent reviews, see: (a) Connell R.D. Expert Opin. Ther. Pat. 12:2002;1763 (b) Boyer S.J. Curr. Top. Med. Chem. 2:2002;973 (c) Bilodeau M.T., Fraley M.E., Hartman G.D. Expert Opin. Investig. Drugs. 11:2002;737.
18. For recent reviews, see: (a) Connell R.D. Expert Opin. Ther. Pat. 12:2002;1763 (b) Boyer S.J. Curr. Top. Med. Chem. 2:2002;973 (c) Bilodeau M.T., Fraley M.E., Hartman G.D. Expert Opin. Investig. Drugs. 11:2002;737.
19. 50 value.
20. 50 value represents the inhibition of VEGF-stimulated mitogenesis as determined in human umbilical vein endothelial cells. Refer to US Patent 6,265,403 for assay details. Values are reported as the average of three determinations for compounds 1 and 3d, and single determinations for 3a, 3e, 3f, and 3h.
21. Partition coefficients were determined by HPLC analysis in octanol/water.
22. 1H NMR and mass spectroscopy.
23. Compounds 2a-f were prepared by the following sequence; for related chemistry; see: Lipshutz B.H., Hungate R.W., McCarthy K.E. J. Am. Chem. Soc. 105:1983;7703.
24. (a) Fraley M.E., Hoffman W.F., Rubino R.S., Hungate R.W., Tebben A.J., Rutledge R.Z., McFall R.C., Huckle W.R., Kendall R.L., Coll K.E., Thomas K.A. Bioorg. Med. Chem. Lett. 12:2002;2767.
25. (b) Fraley M.E., Rubino R.S., Hoffman W.F., Hambaugh S.R., Arrington K.A., Hungate R.W., Bilodeau M.T., Tebben A.J., Rutledge R.Z., Kendall R.L., McFall R.C., Huckle W.R., Coll K.E., Thomas K.A. Bioorg. Med. Chem. Lett. 12:2002;3537.
26. For a description of the ATP binding region of protein tyrosine kinases, see: Traxler P., Furet P. Pharmacol. Ther. 82:1999;195.
27. (a) Conway S.C., Gribble G.W. Heterocycles. 30:1990;627.
28. (b) Yang Y., Martin A.R. Heterocycles. 34:1992;1169.
29. (c) Zheng Q., Yang Y., Martin A.R. Tetrahedron Lett. 34:1993;2235.
30. Additional examples as well as experimental details of the synthetic methods employed in this work can be found in US Patent 6,265,403.